drugset / Trial / NCT06830018
Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
RandomizedParallel-groupOpen-labelSupportive care
Summary
This study is a prospective, randomized, parallel-controlled clinical trial, with the primary objective to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone for the first-line treatment of patients with cancer-related fatigue in gastric or colorectal cancer.
Timeline
- Start
- 2025-01-23
- Primary completion
- 2026-01
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Megestrol Acetate | Other / unclassified | 625 mg | Oral |
Indications
No indication recorded.